PayerTalkCE® Presents: Trends in Cancer Care: Precision Oncology in Rare GI Cancers

Learn About:

1. Epidemiology and burdens of gastroesophageal and biliary tract cancers
2. The importance of early and accurate diagnosis in managing treatment efficacy and cost.
3. The role of personalized medicine and multidisciplinary approaches in the treatment of rare GI cancers

Expert Faculty Presenters:

Shubham Pant, MD Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Click here for biography Laura Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Click here for biography Melinda Bachini Chief Patient Officer Cholangiocarcinoma Foundation Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
In this episode of PayerTalkCE® we will explore the epidemiology and burdens of gastroesophageal and biliary tract cancers. Experts will discuss the importance of early and accurate diagnosis in managing treatment efficacy and cost. The episode will also delve into the role of personalized medicine and multidisciplinary approaches and provide collaborative and actionable insights on how managed care professionals can adapt their strategies to better accommodate the complexities associated with rare GI cancers, ultimately aiming to enhance patient care while managing resource allocation effectively.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe the epidemiology, pathophysiology, and burdens of gastroesophageal adenocarcinomas (GEA) and biliary tract cancers (BTC)
• Outline the biological rationale for targeting HER2 in gastrointestinal malignancies
• Assess how multidisciplinary teams can improve outcomes for patients with GEA and BTC

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners for Advancing Clinical Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners for Clinical Education designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-25-138-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.